Endocrinology Research Analysis
February 2026 endocrinology featured converging mechanistic and translational advances that nominate druggable axes for glycemic control and cardiometabolic risk. Preclinical-to-translational studies uncovered an immunometabolic thromboxane receptor pathway that acutely amplifies skeletal-muscle glucose uptake, and an intestinal aPKC–GLUT1 program that induces glucose excretion—offering insulin-independent levers for diabetes and obesity. Human single-cell multi-omics established an NKX2.2–CLEC1
Summary
February 2026 endocrinology featured converging mechanistic and translational advances that nominate druggable axes for glycemic control and cardiometabolic risk. Preclinical-to-translational studies uncovered an immunometabolic thromboxane receptor pathway that acutely amplifies skeletal-muscle glucose uptake, and an intestinal aPKC–GLUT1 program that induces glucose excretion—offering insulin-independent levers for diabetes and obesity. Human single-cell multi-omics established an NKX2.2–CLEC16A/endosomal axis for pancreatic endocrine differentiation and delivered an intervention-ready T1D-like model. In the clinic, oligonucleotide therapeutics matured (pelacarsen enabling apheresis-sparing Lp(a) lowering), and long-acting endocrine formulations advanced (once-weekly somapacitan non-inferior to daily GH). Across population studies, genomic and imaging tools (APOB genotyping, combined liver–pancreas fat phenotyping) sharpened risk stratification for progressive liver disease and cardiac remodeling.
Selected Articles
1. Thromboxane signalling links immune activation to enhanced glucose uptake in skeletal muscle.
A translational study shows macrophage COX-2–driven thromboxane production with exercise and demonstrates that thromboxane receptor agonism rapidly boosts skeletal-muscle glucose uptake, glycogen synthesis, and whole-body glucose tolerance, with efficacy preserved in obesity. Mechanistic analyses implicate PKA activation and cytoskeletal remodeling that facilitate GLUT4 trafficking.
Impact: Reveals a druggable immunometabolic axis (macrophage COX-2 → thromboxane → TBXA2R) that augments muscle glucose uptake independent of insulin, opening a new therapeutic pathway for insulin-resistant states.
Clinical Implications: Early-phase clinical testing of TBXA2R modulation could assess safety, dose–response, and glucose-lowering efficacy—especially in insulin-resistant or exercise-intolerant populations.
Key Findings
- Exercise increased plasma TXB2 and induced PTGS2 (COX-2) in muscle-resident monocytes/macrophages.
- Thromboxane receptor agonism (I-BOP) increased muscle glucose uptake (up to 2.5×) and glycogen synthesis (~430%) and improved glucose tolerance in vivo, including in obese mice.
- PKA activation and cytoskeletal remodeling linked to GLUT4 trafficking underpinned the metabolic effects.
2. Pelacarsen and lipoprotein(a) apheresis in secondary prevention: the Lp(a)FRONTIERS APHERESIS trial.
A 52-week randomized, placebo-controlled trial in patients with very high Lp(a) and established CVD showed pelacarsen reduced normalized apheresis session rates (0.16 vs 0.93; OR 0.006) and lowered Lp(a) by 72% versus placebo, with overall similar safety aside from mild injection-site erythema.
Impact: Demonstrates that an Lp(a)-targeted oligonucleotide can meaningfully spare apheresis while achieving profound Lp(a) lowering, addressing a high-burden niche in secondary prevention.
Clinical Implications: Clinicians may consider trial referral and counseling for patients with very high Lp(a) and CVD; outcome trials are needed to confirm MACE reduction, but procedural burden can likely be reduced.
Key Findings
- Normalized apheresis session rate was markedly lower with pelacarsen (0.16) versus placebo (0.93), OR 0.006 (P<0.0001).
- Placebo-adjusted change in Lp(a) at 52 weeks was −72% (95% CI −79% to −61%).
- Safety was generally similar between groups, with mild injection-site erythema more common with pelacarsen.
3. Somapacitan in children with idiopathic short stature: a randomised controlled phase 3 study.
In a 52-week phase 3 RCT (n=88), once-weekly somapacitan was non-inferior to daily growth hormone for height velocity in treatment-naïve prepubertal children with idiopathic short stature, with similar safety and lower patient-reported treatment burden.
Impact: Validates a long-acting GH formulation that maintains efficacy while reducing injection frequency—an adherence and quality-of-life advance likely to influence guidelines and practice.
Clinical Implications: Somapacitan can be considered as an alternative to daily GH for idiopathic short stature, with attention to long-term metabolic safety as exposure widens.
Key Findings
- Height velocity at 52 weeks was 10.2 cm/year (somapacitan) vs 10.6 cm/year (daily GH), meeting non-inferiority (ETD −0.3 cm/year).
- Adverse event profiles were similar between groups.
- Patient-reported treatment burden favored once-weekly dosing.
4. Single-cell multi-omic analyses highlight the essential role of NKX2.2-CLEC16A/endosomal pathway for human pancreatic differentiation and function.
Using a human stem-cell platform from pancreatic progenitor to islet, the study maps regulatory networks that govern endocrine fate and identifies an essential NKX2.2–CLEC16A/endosomal axis. CLEC16A knockout yields an autoimmune-like T1D human model and enables discovery of pharmacologic rescuers that restore functional deficits.
Impact: Provides an intervention-ready human model with a mechanistic blueprint for endocrine differentiation, accelerating target discovery and early translational testing for autoimmune diabetes.
Clinical Implications: Suggests new approaches to preserve or restore beta-cell differentiation/function by modulating the NKX2.2–CLEC16A/endosomal pathway; informs candidate targets for early-phase trials.
Key Findings
- Single-cell transcriptomic and chromatin profiling across differentiation defined regulatory networks for endocrine fate.
- An essential NKX2.2–CLEC16A/endosomal axis was required for proper human pancreatic endocrine differentiation.
- CLEC16A knockout produced an autoimmune-like human T1D model and enabled discovery of pharmacologic rescuers.
5. Atypical protein kinase C activation drives intestinal glucose excretion in diabetes mellitus.
Mechanistic work shows that activating atypical PKC in the intestine induces GLUT1-mediated uptake of circulating glucose and its secretion into the lumen, recreating intestinal glucose excretion. Pharmacologic activation with prostratin reproduced the effect without proliferative signaling, nominating the aPKC/GLUT1 axis as a druggable pathway for glycemic lowering and weight loss.
Impact: Identifies a previously unrecognized, druggable intestinal mechanism that directly disposes systemic glucose—distinct from SGLT2 inhibition or bariatric surgery.
Clinical Implications: If safely translated to humans, intestinal aPKC/GLUT1 modulators could become novel insulin-independent glucose-lowering and weight-loss agents; first-in-human safety and dose–response studies are warranted.
Key Findings
- Intestinal aPKC activation reproduced transcriptomic signatures of glucose excretion.
- GLUT1-mediated uptake and luminal excretion of serum glucose increased without proliferative signaling.
- Genetic and pharmacologic activation of intestinal aPKC increased glucose excretion in vivo.